Skip to main content
  • Poster presentation
  • Open access
  • Published:

Dichloroacetate is an effective treatment for sarcoma models in vitro and in vivo


Sarcomas are cancers that arise from tissues of mesenchymal origin and there has been limited improvement in treatments over the last 30 years. The Warburg effect is a widespread metabolic phenotype of cancer, where glycolysis is favoured despite the presence of oxygen. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (PDK) inhibitor in clinical use that can reverse the Warburg effect, inhibiting growth and enhancing apoptosis in a range of cancers. We have investigated its effectiveness against sarcoma cells in vitro and in vivo.

Materials and methods

Three cell lines (mouse fibrosarcoma S180, mouse osteosarcoma K7M2 and human fibrosarcoma HT1080-luc2) were examined for cell viability after DCA treatment in vitro (neutral red uptake assay), alone and in combination with doxorubicin. In vivo, K7M2 cells were injected s.c. into Rag1-/- mice (2 sites per mouse, 7-9 mice per group) and established tumours were treated with DCA in the drinking water (0, 0.5, 1.0 and 1.5 g/L, delivering 0, 70, 125 and 165 mg/kg/day, respectively). Tumour growth was monitored with callipers. Plasma was collected on d1 and d15 for measurement of DCA levels (LC-MS).


DCA significantly reduced the total viable cell number after 48 h of treatment in the mouse sarcoma lines (~15% at 0.5 mM DCA, and 30-40% at 5 mM DCA), however HT1080-luc2 cells showed only a 10% reduction in cell number with 5 mM DCA. There was no morphological indication of apoptosis, suggesting DCA was decreasing proliferation. Chronic treatment of the mouse cells (5 mM DCA for 2 weeks) resulted in significantly slower growth rates as measured over 48 h (7 and 13% total cell number compared to untreated S180 and K7M2 cells, respectively). DCA did not synergise with doxorubicin but was additive at lower concentrations of doxorubicin. In vivo, 1.0 and 1.5 g/L DCA significantly reduced tumour growth (33.0 and 33.1% reduction in tumour size on d13, p=0.001 and 0.01 respectively). Plasma DCA was undetectable on d1 of treatment, but by d15, 1.0 and 1.5 g/L DCA delivered 2-44 uM. Tumour DCA concentrations were also measured and found to be in the range of 25-470 uM, much lower than those typically used in in vitro studies.


DCA was effective against an in vivo sarcoma model, with tumour DCA concentrations in the micromolar range. These concentrations are achievable clinically, thus DCA warrants further investigation for sarcoma treatment.


Supported by the Sarah-Grace Sarcoma Foundation and Cancer Australia.

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rooke, M., Coupland, L.A., Truong, T. et al. Dichloroacetate is an effective treatment for sarcoma models in vitro and in vivo. Cancer Metab 2 (Suppl 1), P9 (2014).

Download citation

  • Published:

  • DOI: